


PHARMACEUTICAL 2023

Regulus Therapeutics Inc. Rank 217 of 446









Regulus Therapeutics Inc. Rank 217 of 446



The relative strengths and weaknesses of Regulus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Regulus Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 53% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	44,079
Cost of Goods Sold	0
Intangible Assets	62
Liabilities, Current	11,657
Liabilities, Non-Current	1,768
Other Assets	2,575
Other Compr. Net Income	-12
Other Expenses	689
Other Liabilities	0
Other Net Income	0
Other Revenues	605
Property and Equipment	0
Research and Development	18,410
Selling, General and Administrative Expense	9,829

Output Variable	Value in 1000 USD
Assets	46,716
Liabilities	13,425
Expenses	28,928
Revenues	605
Stockholders Equity	33,291
Net Income	-28,323
Comprehensive Net Income	-28,329
Economic Capital Ratio	96%

